Frontlight ResearchEarly access
CompletedNo phase
Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease
Key facts
- Who runs it
- Yonsei University
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 222 people enrolled
- Started
- 14 Aug 2020
- Ended
- 13 Dec 2025
- Type of study
- Observational
- Record updated
- 13 July 2026
Who can take part
- Age
- 19 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age ≥ 19 yrs
- Severe aortic stenosis or severe aortic regurgitation
- Agree to consent for self
- Can follow-up for the next 2 years
Who cannot take part
- Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
- Pre-existing acute kidney injury
- On ECMO or IABP
- Life expectancy < 12 months
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)
The group in the trial
- Patients with severe aortic stenosis or severe aortic regurgitation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 July 2026